Retatrutide 5mg*10vials

Weight Loss Efficacy: In a phase 2 clinical trial involving individuals with obesity or overweight, Retatrutide demonstrated significant weight loss capability. After 48 weeks of treatment with a 12 mg weekly dose, participants achieved an average weight reduction of 24.2% (approximately 26 kg). In a study of patients with obesity and knee osteoarthritis, the average weight loss reached up to 28.7% after 68 weeks of treatment.

Dose Dependency: The efficacy showed a positive correlation with dosage. For example, the 8 mg dose group achieved an average weight loss of 22.8% at 48 weeks, compared to 17.1% in the 4 mg group.

High Response Rate: In the 12 mg dose group, 100% of participants achieved a weight loss of ≥5% at 48 weeks, 93% achieved ≥10% loss, and 83% achieved ≥15% loss.

Efficacy in Type 2 Diabetes: In patients with type 2 diabetes, Retatrutide also significantly reduced blood glucose and body weight. After 36 weeks of treatment, the 12 mg dose group showed a 2.16% reduction in HbA1c and a 16.9% reduction in weight, demonstrating superior effects compared to the control drug, dulaglutide.

Benefits for Non-Alcoholic Fatty Liver Disease (NAFLD): Studies indicated that Retatrutide significantly reduces liver fat. In a subgroup of patients with NAFLD, treatment with 8 mg and 12 mg doses for 48 weeks resulted in an average relative liver fat reduction of over 80%, with more than 85% of patients achieving resolution of hepatic steatosis, and no hepatotoxicity was observed.

Effects on Body Composition: A 2025 study published in The Lancet Diabetes & Endocrinology noted that Retatrutide effectively reduces fat while preserving lean mass during weight loss. Treatment with an 8 mg dose for 36 weeks reduced total body fat mass by 26.1%, and the proportion of lean mass lost was similar to that seen with other weight-loss medications, indicating a higher quality of weight loss.